MCID: LNG020
MIFTS: 47

Lung Oat Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Oat Cell Carcinoma

MalaCards integrated aliases for Lung Oat Cell Carcinoma:

Name: Lung Oat Cell Carcinoma 12 15
Carcinoma, Small Cell 43
Oat Cell Carcinoma 12
Carcinoma Oat Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:5411
MeSH 43 D018288
NCIt 49 C3915
UMLS 71 C0262584

Summaries for Lung Oat Cell Carcinoma

MalaCards based summary : Lung Oat Cell Carcinoma, also known as carcinoma, small cell, is related to ovarian small cell carcinoma and small cell carcinoma of the bladder. An important gene associated with Lung Oat Cell Carcinoma is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Neuroscience and G alpha (s) signalling events. The drugs Durvalumab and Atezolizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and prostate, and related phenotype is nervous system.

Related Diseases for Lung Oat Cell Carcinoma

Diseases related to Lung Oat Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 344)
# Related Disease Score Top Affiliating Genes
1 ovarian small cell carcinoma 32.8 SYP ENO2
2 small cell carcinoma of the bladder 32.7 SYP ENO2 CHGA
3 gallbladder small cell carcinoma 32.7 SYP ENO2 CHGA
4 gastric small cell carcinoma 32.5 SYP ENO2 CHGA
5 cervix small cell carcinoma 32.0 SYP ENO2 CHGA
6 urinary bladder small cell neuroendocrine carcinoma 31.6 SYP GRP ENO2 CHGA
7 small cell cancer of the lung 31.5 SYP POMC GRP ENO2 CHGA CALCA
8 laryngeal small cell carcinoma 30.9 TAGLN SYP CNN1 CHGA
9 inappropriate adh syndrome 30.8 POMC AVP
10 large cell carcinoma 30.0 SYP GRP ENO2 CHGA
11 small cell carcinoma 29.9 SYP GRP ENO2 CHGA CALCA
12 merkel cell carcinoma 29.9 SYP ENO2 CHGA
13 diabetes insipidus 29.8 POMC CALCA AVP
14 somatostatinoma 29.7 ENO2 CHGA CALCA
15 exophthalmos 29.7 SYP ENO2
16 carcinoid syndrome 29.7 SYP ENO2 CHGA CALCA
17 primary hyperparathyroidism 29.7 POMC CHGA CALCA
18 endometrial small cell carcinoma 29.6 SYP ENO2 CHGA
19 large cell neuroendocrine carcinoma 29.5 SYP ENO2 CHGA
20 tubular adenocarcinoma 29.5 SYP ENO2 CHGA
21 conn's syndrome 29.5 POMC CHGA CALCA
22 suppression of tumorigenicity 12 29.5 SYP GRP ENO2 CHGA
23 lung large cell carcinoma 29.4 SYP CHGA
24 thyroid gland medullary carcinoma 29.3 CHGA CALCA
25 islet cell tumor 29.2 SYP ENO2 CHGA CALCA
26 neuroendocrine carcinoma 29.1 SYP GRP ENO2 CHGA CALCA
27 constipation 29.0 GRP CHGA CALCA
28 thyroid carcinoma, familial medullary 28.9 POMC GRP CHGA CALCA
29 neuroendocrine tumor 28.3 SYP POMC GRP ENO2 CHGA CALCA
30 prostate small cell carcinoma 11.7
31 esophagus small cell carcinoma 11.6
32 thymus small cell carcinoma 11.3
33 small-cell carcinoma of the ovary of hypercalcemic type 11.3
34 lymphocytic hypophysitis 10.4 POMC ENO2
35 pituitary infarct 10.4 POMC AVP
36 tuberculous epididymitis 10.4 POMC AVP
37 hypothalamic disease 10.4 POMC AVP
38 sheehan syndrome 10.4 POMC AVP
39 vaginal glandular tumor 10.4 ENO2 CHGA
40 pituitary apoplexy 10.4 POMC AVP
41 ureter transitional cell carcinoma 10.4 ENO2 CHGA
42 pulmonary artery leiomyosarcoma 10.4 GRP ENO2
43 goblet cell carcinoid 10.3 ENO2 CHGA
44 myxedema 10.3 POMC AVP
45 gastric gastrinoma 10.3 ENO2 CHGA
46 nodular ganglioneuroblastoma 10.3 ENO2 CHGA
47 ewing sarcoma of bone 10.3 ENO2 CHGA
48 malignant melanocytic neoplasm of the peripheral nerve sheath 10.3 SYP ENO2
49 appendix lymphoma 10.3 ENO2 CHGA
50 motion sickness 10.3 POMC AVP

Graphical network of the top 20 diseases related to Lung Oat Cell Carcinoma:



Diseases related to Lung Oat Cell Carcinoma

Symptoms & Phenotypes for Lung Oat Cell Carcinoma

MGI Mouse Phenotypes related to Lung Oat Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.23 AVP CHGA ENO2 GRP OAT POMC

Drugs & Therapeutics for Lung Oat Cell Carcinoma

Drugs for Lung Oat Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Durvalumab Approved, Investigational Phase 3 1428935-60-7
2
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
3
Camptothecin Experimental Phase 3 7689-03-4
4 Amrubicin Investigational Phase 3 110267-81-7
5
BCG vaccine Investigational Phase 3
6
Tremelimumab Investigational Phase 3 745013-59-6
7 Hematinics Phase 3
8 Epoetin alfa Phase 3 113427-24-0
9 Immunologic Factors Phase 2, Phase 3
10 Pharmaceutical Solutions Phase 3
11 Immunoglobulins Phase 2, Phase 3
12 Antibodies Phase 2, Phase 3
13 Antibodies, Monoclonal Phase 2, Phase 3
14
Apatinib Phase 3 811803-05-1
15
Pasireotide Approved Phase 2 396091-73-9 9941444
16
Bevacizumab Approved, Investigational Phase 2 216974-75-3
17
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
18
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
20
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
21
Lenograstim Approved, Investigational Phase 2 135968-09-1
22
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
23
Topotecan Approved, Investigational Phase 1, Phase 2 123948-87-8, 119413-54-6 60700
24
Pembrolizumab Approved Phase 2 1374853-91-4
25
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
26
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
27
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
28
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
29
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
30
Somatostatin Approved, Investigational Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605
31
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
32
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
33
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
34
Ipilimumab Approved Phase 2 477202-00-9
35
nivolumab Approved Phase 2 946414-94-4
36
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
37
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
38
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
39
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
40
Etoposide Approved Phase 2 33419-42-0 36462
41
Olaparib Approved Phase 2 763113-22-0 23725625
42
Pomalidomide Approved Phase 1, Phase 2 19171-19-8
43
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
44
leucovorin Approved Phase 2 58-05-9 6006 143
45
Gemcitabine Approved Phase 2 95058-81-4 60750
46 Bemiparin Approved, Investigational Phase 2 91449-79-5
47
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
48
Coal tar Approved Phase 2 8007-45-2
49
Zoledronic Acid Approved Phase 2 118072-93-8 68740
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
2 Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer Unknown status NCT02688036 Phase 3
3 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer Unknown status NCT02772107 Phase 2, Phase 3 Temozolomide;first-line chemotherapy
4 Randomized Study Comparing Two Strategies Carboplatin and Etoposide Topotecan in Patients With SCLC on the Second Row With Relapsed at Least Three Months After Initial Response to Chemotherapy With Platinum-etoposide 6 Cycles Unknown status NCT02738346 Phase 3 Carboplatin;Etoposide;Topotecan
5 The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
6 Randomized, Phase III Trial Comparing Etoposide/Cisplatin (EP) With Irinotecan/Cisplatin (IP) in Patients With Previously Untreated, Extensive Disease (ED) Small Cell Lung Cancer (SCLC) Completed NCT00349492 Phase 3 IP
7 A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE) Completed NCT03061812 Phase 3 Rovalpituzumab tesirine;Topotecan
8 A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF Completed NCT00144989 Phase 3 Etoposide and cisplatin after chemoradiotherapy;Irinotecan and cisplatin after chemoradiotherapy
9 AMR PH GL 2007 CL001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy Completed NCT00547651 Phase 3 Amrubicin;Topotecan
10 A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy Completed NCT00270166 Phase 3 epoetin alfa
11 Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer Recruiting NCT04192682 Phase 2, Phase 3 Anlotinib Hydrochloride
12 A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) Recruiting NCT03703297 Phase 3 Durvalumab;Tremelimumab
13 MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) Recruiting NCT04155034 Phase 3
14 Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer Recruiting NCT02635009 Phase 2, Phase 3
15 Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab Recruiting NCT03811002 Phase 2, Phase 3 Atezolizumab;Carboplatin;Cisplatin;Etoposide
16 A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN) Active, not recruiting NCT03043872 Phase 3 Durvalumab;Tremelimumab;Carboplatin;Cisplatin;Etoposide
17 A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer Active, not recruiting NCT03699956 Phase 3 Cisplatin/carboplatin plus etoposide
18 A Randomized Controlled Study of Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide and Cisplatin Chemotherapy Not yet recruiting NCT02875457 Phase 3 apatinib;etoposide and cisplatin;placebo;etoposide and cisplatin
19 Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial Not yet recruiting NCT04402788 Phase 2, Phase 3 Atezolizumab
20 Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer Unknown status NCT01900951 Phase 2 Temozolomide
21 Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Nab-paclitaxel as a Single Agent in the Small Cell Lung Cancer Patients With Extensive Disease and Failed to First Line/ Second Line Chemotherapy Unknown status NCT02262897 Phase 2 Nab-paclitaxel
22 Maintenance Immunotherapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer Unknown status NCT01592422 Phase 2
23 Phase Ⅱ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer Unknown status NCT01635400 Phase 2 Irinotecan
24 Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer Patients With ECOG PS 2 Unknown status NCT00906061 Phase 2 Gemcitabine and Docetaxel
25 A Phase II Trial of SOM230(PasireotideLAR) and Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer Unknown status NCT01417806 Phase 2 Topotecan and Pasireotide
26 An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer Completed NCT00412880 Phase 2 BI 2536
27 Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer Completed NCT00191750 Phase 2 Pemetrexed
28 Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC) Completed NCT00298896 Phase 2 SNS-595
29 A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00294931 Phase 2 irinotecan;carboplatin;bevacizumab
30 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
31 Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer Completed NCT00046787 Phase 2 OSI-211 (Liposomal Lurtotecan)
32 A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00305942 Phase 2 Topotecan;carboplatin
33 A Phase 2 Trial of Single-Agent Amrubicin in Patients With Extensive Disease Small Cell Lung Cancer That is Refractory or Progressive Within 90 Days of Completion of First Line Platinum-based Chemotherapy Completed NCT00375193 Phase 2 Amrubicin
34 Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-line Therapy in Chemotherapy-naïve Patients With Extensive-disease (ED) Stage Small-cell Lung Cancer (SCLC) Completed NCT00359359 Phase 1, Phase 2 Sagopilone (BAY86-5302, ZK 219477);Cisplatin
35 A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Completed NCT00284154 Phase 2 Vinflunine
36 Phase II Study of Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Patients With Limited Stage Small Cell Lung Cancer Completed NCT00308529 Phase 2 irinotecan;carboplatin;bevacizumab
37 A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer Completed NCT00116610 Phase 2 picoplatin
38 A Randomized Phase 2 Trial Comparing Amrubicin Versus Topotecan as Second-Line Treatment in Patients With Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy Completed NCT00319969 Phase 2 Amrubicin;Topotecan
39 A Phase IIb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Relapsed Small Cell Lung Cancer Completed NCT01497873 Phase 2 Topotecan;Belotecan
40 A Single Arm, Two-Stage Phase II Study of Arsenic Trioxide in Previously Treated Small Cell Lung Cancer Completed NCT01470248 Phase 2 Arsenic Trioxide
41 Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Completed NCT02499770 Phase 1, Phase 2 Carboplatin;Placebo;Trilaciclib;Etoposide
42 Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer Completed NCT01901653 Phase 1, Phase 2 Rovalpituzumab tesirine (SC16LD6.5)
43 Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES) Completed NCT00388960 Phase 2 Amrubicin;Cisplatin;Etoposide
44 Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer Completed NCT00374140 Phase 2 RAD001 (everolimus)
45 Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma Completed NCT00531284 Phase 1, Phase 2 Carfilzomib;Dexamethasone
46 A Phase II Study of NK012 in Sensitive Relapsed and Refractory Relapsed Small-Cell Lung Cancer (SCLC) Completed NCT00951613 Phase 2 NK012
47 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
48 Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer Completed NCT00695292 Phase 2 irinotecan;Carboplatin;sunitinib
49 Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer Completed NCT00643396 Phase 2
50 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2

Search NIH Clinical Center for Lung Oat Cell Carcinoma

Cochrane evidence based reviews: carcinoma, small cell

Genetic Tests for Lung Oat Cell Carcinoma

Anatomical Context for Lung Oat Cell Carcinoma

MalaCards organs/tissues related to Lung Oat Cell Carcinoma:

40
Lung, Brain, Prostate, Cervix, Bone, Thymus, Lymph Node

Publications for Lung Oat Cell Carcinoma

Articles related to Lung Oat Cell Carcinoma:

(show top 50) (show all 728)
# Title Authors PMID Year
1
Neurophysins as markers of vasopressin and oxytocin release. A study in carcinoma of the lung. 61 54
1966564 1990
2
Nerve root metastasis of gastric adenocarcinoma: A case report and review of the literature. 61
31302320 2019
3
Oat-cell carcinoma of the tongue. 61
26956201 2016
4
Small cell carcinoma of the urinary bladder: changing trends in the current literature. 61
26889739 2016
5
The role of immunohistochemistry in the analysis of the spectrum of small round cell tumours at a tertiary care centre. 61
23998069 2013
6
Squamous cell carcinoma lung with progressive systemic sclerosis. 61
23781672 2012
7
Endoscopic ultrasound-guided biopsies for mediastinal lesions and lymph node diagnosis and staging. 61
22179163 2011
8
Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. 61
21232206 2010
9
Survival in a patient with severe paraneoplastic hyponatremia: a case report. 61
18928542 2008
10
Merkel cell carcinoma: treatment with bleomycin. 61
19061585 2008
11
[Small (oat)-cell carcinoma of the gastrointestinal tract]. 61
18341909 2008
12
Merkel cell carcinoma of the upper extremity: case report and an update. 61
18328106 2008
13
A note from history: the saga of carcinoid and oat-cell carcinoma. 61
18988939 2008
14
Cancer-associated retinopathy (CAR) with electronegative ERG: a case report. 61
17721792 2008
15
[Oat-cell carcinoma of the esophagus: presentation of two cases and literature review]. 61
17973588 2007
16
Isolated frontal disequilibrium as presenting form of anti-Hu paraneoplastic encephalomyelitis. 61
17266086 2007
17
F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases. 61
16855436 2006
18
[Oat cell carcinoma of the common bile duct]. 61
16796953 2006
19
Oat cell carcinoma of the oesophagus--a case report and review of literature. 61
16498759 2005
20
[Diabetes insipidus in a patient with small-cell lung cancer: a paradox?]. 61
16392186 2005
21
Extra-pulmonary oat cell carcinoma: report of two cases. 61
16022138 2005
22
(18)FDG PET in primary oat cell carcinoma of the esophagus. 61
15805695 2005
23
Primary oat cell carcinoma of the breast: imaging features. 61
15385324 2004
24
Small-cell carcinomas of the gastrointestinal tract: a review. 61
15226341 2004
25
Progressive encephalomyelitis with rigidity: a paraneoplastic presentation of oat cell carcinoma of the lung. Case report. 61
15273862 2004
26
[Paraneoplastic syndromes in ENT surgery]. 61
12682737 2003
27
Case report: esophageal collision tumor (oat cell carcinoma and adenocarcinoma) in Barrett's esophagus: immunohistochemical, electron microscopy and LOH analysis. 61
12507278 2003
28
Invasive papillary carcinomas of the extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases. 61
12481004 2002
29
Retinochoroidal mass: a presenting feature of metastatic oat cell carcinoma of lung. 61
12510727 2002
30
Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide. 61
12136524 2002
31
Extrapulmonary oat-cell carcinoma presenting as a primary left ventricular tumor: a case report. 61
12011814 2002
32
[Oat cell carcinoma of the bladder]. 61
12090189 2002
33
[A case of central diabetes insipidus caused by metastatic small cell lung cancer]. 61
11974872 2002
34
Combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of lung cancer. 61
11722067 2001
35
[Oat-cell carcinoma of the tongue: report of a case]. 61
11526653 2001
36
Paraneoplastic limbic encephalitis associated with bronchogenic carcinoma: a case report. 61
11447443 2001
37
Metastases to the products of conception from a maternal bronchial carcinoma. A case report and review of literature. 61
11769401 2001
38
Oat-cell carcinoma of the prostate. Diagnosis, prognosis and therapeutic implications. 61
11598447 2001
39
Lung cancer screening results in the National Cancer Institute New York study. 61
11147612 2000
40
Primary small cell (oat cell) carcinoma of the breast: report of a case and review of the literature. 61
11107070 2000
41
Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. 61
10912951 2000
42
[Small-cell carcinoma of the larynx]. 61
10804124 2000
43
[Oat cell bladder carcinoma. Report of a case]. 61
10730427 2000
44
Differentiation between merkel cell carcinoma and malignant melanoma: An immunohistochemical study. 61
11053914 2000
45
[Report of a new case of small-cell carcinoma of the bladder and review of the literature]. 61
10670131 1999
46
Sinonasal undifferentiated carcinoma: a distinctive clinicopathologic entity. 61
10562893 1999
47
Lambert-eaton myasthenic syndrome in association with transitional cell carcinoma: a previously unrecognized association. 61
10754123 1999
48
Contemporary evaluation and management of Cushing's syndrome. 61
10096147 1999
49
[A case of paraneoplastic cerebellar degeneration associated with small cell lung cancer]. 61
10214046 1999
50
[Evaluation of nervous system disorders during the course of gastric carcinoma on the basis of clinical electrophysiologic analysis]. 61
10909489 1999

Variations for Lung Oat Cell Carcinoma

Cosmic variations for Lung Oat Cell Carcinoma:

9 (show top 50) (show all 1540)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 6
2 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 6
3 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 6
4 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 6
5 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 6
6 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
7 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 6
8 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 6
9 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 6
10 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 6
11 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 6
12 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 6
13 COSM145430147 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1467C>G p.F489L 19:4947122-4947122 6
14 COSM127070824 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.2691A>T p.Q897H 8:102305221-102305221 6
15 COSM127059821 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.1555A>G p.S519G 8:102326590-102326590 6
16 COSM85195038 U2AF1 lung,NS,carcinoma,undifferentiated carcinoma c.319G>C p.D107H 21:43095467-43095467 6
17 COSM130300868 TYK2 lung,NS,carcinoma,undifferentiated carcinoma c.3560G>T p.C1187F 19:10350838-10350838 6
18 COSM131090496 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.1922C>T p.S641L 14:81143980-81143980 6
19 COSM131094722 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.412C>T p.L138F 14:81091088-81091088 6
20 COSM131094002 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.937A>C p.K313Q 14:81142995-81142995 6
21 COSM87049256 TSC2 lung,NS,carcinoma,undifferentiated carcinoma c.1840G>T p.A614S 16:2071510-2071510 6
22 COSM85721789 TSC1 lung,NS,carcinoma,undifferentiated carcinoma c.694G>T p.E232* 9:132921406-132921406 6
23 COSM90140992 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1193C>T p.P398L 16:2173978-2173978 6
24 COSM90145840 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1287C>G p.Y429* 16:2174274-2174274 6
25 COSM87090089 TRAF5 lung,NS,carcinoma,undifferentiated carcinoma c.302G>C p.R101T 1:211356392-211356392 6
26 COSM87898991 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.535C>T p.H179Y 17:7675077-7675077 6
27 COSM87901497 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.461G>T p.G154V 17:7675151-7675151 6
28 COSM87935416 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.499C>T p.Q167* 17:7675113-7675113 6
29 COSM87904420 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.514G>T p.V172F 17:7675098-7675098 6
30 COSM87898444 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.536A>G p.H179R 17:7675076-7675076 6
31 COSM87906107 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.473G>T p.R158L 17:7675139-7675139 6
32 COSM87909792 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.919+1G>T p.? 17:7673700-7673700 6
33 COSM87940740 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.811G>T p.E271* 17:7673809-7673809 6
34 COSM87899785 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.991C>T p.Q331* 17:7673537-7673537 6
35 COSM87902162 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.783-1G>T p.? 17:7673838-7673838 6
36 COSM87915599 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.842A>G p.D281G 17:7673778-7673778 6
37 COSM87897914 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.527G>T p.C176F 17:7675085-7675085 6
38 COSM87899377 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.375+1G>A p.? 17:7675993-7675993 6
39 COSM87900565 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.1024C>T p.R342* 17:7670685-7670685 6
40 COSM87918616 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.993+1G>A p.? 17:7673534-7673534 6
41 COSM87897711 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.818G>A p.R273H 17:7673802-7673802 6
42 COSM87900157 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.818G>T p.R273L 17:7673802-7673802 6
43 COSM87942817 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.376-1G>T p.? 17:7675237-7675237 6
44 COSM87903076 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.796G>T p.G266* 17:7673824-7673824 6
45 COSM87898836 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.560-1G>A p.? 17:7674972-7674972 6
46 COSM87898881 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.578A>G p.H193R 17:7674953-7674953 6
47 COSM150205149 TLR4 lung,NS,carcinoma,undifferentiated carcinoma c.337C>A p.P113T 9:117712465-117712465 6
48 COSM85378871 TLR2 lung,NS,carcinoma,undifferentiated carcinoma c.1169A>G p.Q390R 4:153704076-153704076 6
49 COSM90180942 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.5624C>T p.S1875L 9:35705660-35705660 6
50 COSM90180404 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.1087C>T p.P363S 9:35721665-35721665 6

Expression for Lung Oat Cell Carcinoma

Search GEO for disease gene expression data for Lung Oat Cell Carcinoma.

Pathways for Lung Oat Cell Carcinoma

Pathways related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 SYP POMC ENO2 CALCA AVP
2 11.3 POMC CALCA AVP
3 10.69 CNN1 CALCA

GO Terms for Lung Oat Cell Carcinoma

Cellular components related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 POMC GRP ENO2 CHGA CALCA AVP
2 secretory granule GO:0030141 8.8 POMC CHGA AVP

Biological processes related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.33 POMC GRP CALCA
2 regulation of blood pressure GO:0008217 9.13 POMC CHGA CALCA
3 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 8.62 GRP CHGA

Molecular functions related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.26 POMC GRP CALCA AVP
2 neuropeptide hormone activity GO:0005184 9.16 GRP AVP
3 hormone activity GO:0005179 8.8 POMC CALCA AVP

Sources for Lung Oat Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....